肝脏 ›› 2024, Vol. 29 ›› Issue (11): 1349-1351.

• 肝癌 • 上一篇    下一篇

复发性肝细胞癌射频消融术后超声造影参数变化观察

赵彬彬, 王洁, 李林雪, 曹玉, 郝建华   

  1. 041000 山西省临汾市人民医院肿瘤科
  • 收稿日期:2023-11-15 出版日期:2024-11-30 发布日期:2025-01-10
  • 通讯作者: 郝建华,Email:hjh18003578150@163.com
  • 基金资助:
    山西省基础研究计划项目(20210302123286)

Changes of CEUS parameters after radiofrequency ablation for recurrent hepatocellular carcinoma

ZHAO Bin-bin, WANG Jie, LI Lin-xue, CAO Yu, HAO Jian-hua   

  1. Department of Oncology, People’s Hospital of Linfen City, Shanxi, 041000, China
  • Received:2023-11-15 Online:2024-11-30 Published:2025-01-10
  • Contact: HAO Jian-hua,Email:hjh18003578150@163.com

摘要: 目的 观察复发性肝细胞癌(RHCC)射频消融术后超声造影(CEUS)参数变化。方法 选择临汾市人民医院2017年1月至2021年1月收治的RHCC患者126例。患者均接受射频消融治疗,分别于治疗后1 d、治疗后6个月进行CEUS检查,根据6个月内患者是否复发将其分为复发组11例和未复发组115例,比较两组平均渡越时间(MTT)、达峰时间(TTP)、峰值强度(PI)。以受试者工作特征曲线(ROC)分析CEUS指标预测射频消融治疗RHCC的价值。结果 复发组与未复发组MTT分别为(59.18±15.37)s、(43.36±14.48)s, TTP分别为(38.55±12.09)s、(29.51±11.26)s,PI分别为(22.74±7.42)dB、(21.05±6.19)dB;与未复发组相比,复发组MTT、TTP较长(P<0.05);而PI差异无统计学意义(P>0.05)。经ROC分析,MTT、TTP预测射频消融治疗RHCC后6个月内复发的曲线下面积分别为0.968(95% CI:0.927~1.000)、0.871(95% CI:0.768~0.974),敏感度分别为0.818、0.727,特异度分别为0.804、0.713,MTT≥56.706 s、TTP≥33.185 s是RHCC患者接受射频治疗后6个月内复发的最佳截断值。结论 MTT、TTP可用于预测射频消融治疗RHCC患者的预后,其灵敏度和特异度较高。

关键词: 肝细胞癌, 复发, 射频消融, 超声造影

Abstract: Objective To observe the changes of Contrast-enhanced ultrasound (CEUS) parameters after radiofrequency ablation of recurrent hepatocellular carcinoma (RHCC). Methods A total of 126 RHCC patients admitted to our hospital from January 2017 to January 2021 were selected as the study subjects. All patients received radiofrequency ablation, and CEUS examination was performed 1day and 6 months after treatment, respectively. Patients were divided into a recurrence group (n=11) and a non-recurrence group (n=115) according to whether they relapsed within 6 months. The mean transit time (MTT), time to peak (TTP) and peak intensity (PI) of the two groups were compared. We used the ROC analysis to test the CEUS indicators’ predictive ability in the prognosis of patients who treated by a radiofrequency ablation (RFA) therapy for RHCC. Results MTT of the two groups were (59.18±15.37) s, (43.36±14.48) s, TTP of the two groups were (38.55±12.09) s, (29.51±11.26) s, PI of the two groups were (22.74±7.42) dB, (21.05±6.19) dB, respectively. Compared with non-recurrence group, the recurrence group had longer MTT and TTP (P<0.05) and there was no significant difference in PI between the two groups (P>0.05). According to ROC analysis, the area under curve of MTT and TTP for predicting recurrence within 6 months after RFA treatment of RHCC were 0.968 (95%CI: 0.927-1.000) and 0.871 (95%CI: 0.768-0.974), the sensitivity was 0.818 and 0.727, and the specificity was 0.804 and 0.713, respectively. MTT ≥ 56.706s and TTP ≥ 33.185s were the best truncation values for recurrence within 6 months after RHCC patients received RFA therapy (both P<0.05). Conclusion After RFA, the ultrasound parameters of RHCC patients with different prognosis were different in CEUS examination. CEUS can be used to predict the prognosis of RHCC patients after radiofrequency ablation with high sensitivity and specificity.

Key words: Hepatocellular carcinoma, Recurrence, Radiofrequency ablation, Ultrasonic imaging